Hemal Nayak is a Cardiology physician affiliated with The University of Texas at San Antonio Health Science Center. OpenAlex indexes 173 publications with 4,668 citations (h-index 32); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8300 Floyd Curl Dr Fl 3
San Antonio, TX 782293931
Telephone
210-450-4888Provider last certified this registry record 23 Jan 2023.
Clinical trials
- Intravascular Ultrasound (IVUS) Imaging During Transvenous Lead Extraction
Sponsor: University of Chicago
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
33 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Program year202516 payments$12,937openpaymentsdata.cms.gov ↗
- Boston Scientific CorporationProgram year202515 payments
- Abbott LaboratoriesProgram year202517 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
65.2%Beta blocker34.4%Metoprolol Succinate52%Metoprolol Tartrate25%Sotalol14%Carvedilol9%Part D<11 patientsAntiarrhythmic20.9%Flecainide Acetate53%Amiodarone Hcl27%Multaq20%Part D<11 patients+ 3 more classes in this area
Blood & clotting
34.8%Factor Xa inhibitor30.4%Eliquis64%Xarelto36%Part D≥31 patientsP2Y12 inhibitor4.4%Clopidogrel100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Atrioesophageal Fistula Rates Before and After Adoption of Active Esophageal Cooling During Atrial Fibrillation Ablation
JACC. Clinical electrophysiology
2023 - Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
Clinical Research in Cardiology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Marcos Restrepo, MD, MSc
The University of Texas at San Antonio Health Science Center
Robert Brzyski, MD
The University of Texas at San Antonio Health Science Center
Devjit Tripathy, MD
The University of Texas at San Antonio Health Science Center
Robert Svatek, MD
The University of Texas at San Antonio Health Science Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”